IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

← catalyst calendar

NCT05987332 · readout in 149 d

Sponsored by IDEAYA Biosciences (industry) · IDYA — their whole pipeline →.

Phase

Phase 2/3

Status

Active, not recruiting

Study type

Interventional

Design

Randomized · None · Treatment

Enrollment

420estimated

Sites

Countries

Australia, Belgium, Canada +10

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2023-10-31

actual

When the study began enrolling

Primary completion

2027-01-15

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2028-01-15

estimated

The whole study's end, after follow-up

First posted

2023-08-14

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-02-17

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Metastatic Uveal Melanoma

Interventions

Drug: IDE196 — also filed as Darovasertib
Drug: Crizotinib — also filed as XALKORI
Drug: Pembrolizumab — also filed as Keytruda
Drug: Ipilimumab — also filed as Yervoy
Drug: Nivolumab — also filed as Opdivo
Drug: Dacarbazine — also filed as DTIC-Dome

Primary outcomes

what the primary-completion date above is the date OF

Phase 2a: To determine the optimal dose of IDE196 + Crizotinib combination for Phase 2B and Phase 3 by evaluating the following:

measured Approximately 5 months

Phase 2 Progression-Free Survival (PFS)

measured Approximately 2 years

Phase 3 Overall Survival (OS) of IDE196 + Crizotinib compared to investigator's choice of treatment.

measured Approximately 4 years

Permalink · IDYA's whole pipeline · Catalyst calendar · Every registered study · What changed